{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:21:31Z","timestamp":1744172491209,"version":"3.40.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41433-025-03681-w","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:39:46Z","timestamp":1739954386000},"page":"1227-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Letter in reply to: Enhancing the understanding of anti-VEGF treatment failure in retinal vascular diseases: a call for expanded analyses and threshold validation"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-6912","authenticated-orcid":false,"given":"Dun Jack","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Faes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"3681_CR1","doi-asserted-by":"crossref","first-page":"g5060","DOI":"10.1136\/bmj.g5060","volume":"349","author":"M Wolkewitz","year":"2014","unstructured":"Wolkewitz M, Cooper BS, Bonten MJM, Barnett AG, Schumacher M. Interpreting and comparing risks in the presence of competing events. BMJ. 2014;349:g5060.","journal-title":"BMJ"},{"key":"3681_CR2","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36:4391\u201300.","journal-title":"Stat Med"},{"key":"3681_CR3","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389\u2013430.","journal-title":"Stat Med."},{"key":"3681_CR4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P. Intravitreal afibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363.","journal-title":"Lancet"},{"key":"3681_CR5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ophtha.2016.09.021","volume":"124","author":"JF Payne","year":"2017","unstructured":"Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes. Ophthalmology. 2017;124:74\u201381.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03681-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:38:20Z","timestamp":1744115900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03681-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03681-w","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Allergan (an AbbVie company, Irvine, CA, USA). The sponsor or funding organisation participated in the review and approval of the manuscript as report 1 of the investigator-initiated trial grant SIMD1004 (this manuscript represents report 1 of at least 2 to come from SIMD1004). No honoraria or payments were made for authorship. DJF: Funding\/fees outside the submitted work with Allergan, Apellis, Google Health and DeepMind. Member of the Eye editorial board. SS: Funding\/fees from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Novo Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics. Sanofi. Member of the Eye editorial board. LF: Other relevant financial activities outside the submitted work with Bayer and Allergan. Member of the Eye editorial board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}